<!DOCTYPE html>
<html>
<head>
<title>Suliqua, INN - insulin glargine + lixisenatide</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:214pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 50 microgram/ml solution for injection in pre-filled pen  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each pre-filled pen contains 300 units of insulin glargine* and 150 micrograms lixisenatide in 3 ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each ml contains 100 units of insulin glargine and 50 micrograms of lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each dose step contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 33 microgram/ml solution for injection in pre-filled pen  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each pre-filled pen contains 300 units of insulin glargine and 100 micrograms of lixisenatide in 3 ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each ml contains 100 units of insulin glargine and 33 micrograms of lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each dose step contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*Insulin glargine is produced by recombinant DNA technology in </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Escherichia coli</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The dose window on the pen shows the number of dose steps. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient(s) with known effects  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each ml contains 2.7 milligrams of metacresol. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Solution for injection in pre-filled pen (SoloStar) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clear colourless solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sodium-glucose co-transporter-2 (SGLT-2) inhibitors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For study results with respect to effect on glycaemic control, and the populations studied, see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.4 and 5.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is available in two pre-filled pens, providing different dosing options, i.e. Suliqua (10-40) pen,</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua (30-60) pen respectively. The differentiation between the pen strengths is based on the dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">range of the pen. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 50 micrograms/ml pre-filled pen delivers dose steps from </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10-40 units</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine in combination with </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5-20 mcg</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of lixisenatide (Suliqua (10-40) pen). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua 100 units/ml + 33 micrograms/ml pre-filled pen delivers dose steps from </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">30-60 units</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine in combination with</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> 10-20 mcg</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of lixisenatide (Suliqua (30-60) pen). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">To avoid medication errors, the prescriber must make sure that the correct strength and number of dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">steps is stated in the prescription (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The dose must be individualised based on clinical response and is titrated based on the patient&#x2019;s need </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for insulin. The lixisenatide dose is increased or decreased along with insulin glargine dose and also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">depends on which pen is used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Starting dose</span></i><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therapy with basal insulin or glucagon-like peptide-1 (GLP-1) receptor agonist or oral glucose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lowering medicinal product other than metformin and SGLT-2 inhibitors should be discontinued prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to initiation of Suliqua.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The starting dose of Suliqua is based on previous anti-diabetic treatment, and in order not to exceed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended lixisenatide starting dose of 10 mcg: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:331pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Previous therapy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin na&#xef;ve </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:235pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">patients (oral </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:237pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">anti-diabetic </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">treatment or </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:229pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">GLP-1 receptor </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:248pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">agonist) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:333pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:332pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(100 units/ml)** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:332pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">20 to &lt;30 units </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:438pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:437pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(100 units/ml)** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:438pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">30 to </span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">&#x2264;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">60 units </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Starting </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">dose  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">and pen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(10-40) pen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:237pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10 dose steps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(10 units/5 mcg)* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 dose steps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:328pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(20 units/10 mcg)*</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:431pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:125pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(30-60) pen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:224pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:319pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:446pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30 dose steps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:433pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(30 units/10 mcg)*</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:80pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* Units insulin glargine (100 units/ml)/mcg lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:80pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients on less than 20 units of insulin glargine may be considered similar to insulin naive patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">**</span></b><b><span style="font-family:Calibri,sans-serif;font-size:11.04pt"> </span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">If a different basal insulin was used: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:77pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For twice daily basal insulin or insulin glargine (300 units/ml), the total daily dose previously </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">used should be reduced by 20% to choose the Suliqua starting dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:77pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For any other basal insulin the same rule as for insulin glargine (100 units/ml) should be applied </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The maximum daily dose is 60 units insulin glargine and 20 mcg lixisenatide corresponding to 60 dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">steps.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua should be injected once a day within one hour prior to a meal. It is preferable that the prandial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injection is performed before the same meal every day, when the most convenient meal has been chosen.</span><tt><span style="font-family:CourierNewPSMT,monospace;font-size:9.96pt"> </span></tt><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dose titration</span></i><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is to be dosed in accordance with the individual patient&apos;s need for insulin. It is recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to optimise glycaemic control via dose adjustment based on fasting plasma glucose (see section 5.1).</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Close glucose monitoring is recommended during the transfer and in the following weeks. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the patient starts with the Suliqua (10-40) pen, the dose may be titrated up to 40 dose steps with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">this pen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For doses &gt;40 dose steps/day titration must be continued with Suliqua (30-60) pen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the patient starts with the Suliqua (30-60) pen, the dose may be titrated up to 60 dose steps with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">this pen.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For total daily doses &gt;60 dose steps/day, Suliqua must not be used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients adjusting the amount or timing of dosing should only do so under medical supervision with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">appropriate glucose monitoring (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Missed dose </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a dose of Suliqua is missed, it should be injected within the hour prior to the next meal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special population  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua can be used in elderly patients. The dose should be adjusted on an individual basis, based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucose monitoring. In the elderly, progressive deterioration of renal function may lead to a steady </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decrease in insulin requirements. For lixisenatide no dose adjustment is required based on age. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapeutic experience of Suliqua </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in patients &#x2265;75</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years of age is limited. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is not recommended in patients with severe renal impairment and end-stage renal disease as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">there is no sufficient therapeutic experience with use of lixisenatide.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is required for lixisenatide in patients with mild or moderate renal impairment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment, insulin requirements may be diminished due to reduced insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolism.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate renal impairment using Suliqua, frequent glucose monitoring and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment may be necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment of lixisenatide is needed in patients with hepatic impairment (see section 5.2). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gluconeogenesis and reduced insulin metabolism. Frequent glucose monitoring and dose adjustment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be necessary for Suliqua in patients with hepatic impairment</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">. </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no relevant use of Suliqua in the paediatric population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is to be injected subcutaneously in the abdomen, deltoid, or thigh. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The injection sites should be rotated within the same region (abdomen, deltoid, or thigh) from one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be instructed to always use a new needle. The re-use of insulin pen needles increases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the risk of blocked needles, which may cause under- or overdosing.</span><tt><span style="font-family:CourierNewPSMT,monospace;font-size:9.96pt"> </span></tt><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the event of blocked needles, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients must follow the instructions described in the Instructions for Use accompanying the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leaflet (see section 6.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua must not be drawn from the cartridge of the pre-filled pen into a syringe to avoid dosing errors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and potential overdose (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Traceability  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the name and the batch number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the administered product should be clearly recorded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Type 1 diabetes mellitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ketoacidosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rotation of the injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">absorption and worsened glycaemic control following insulin injections at sites with these reactions. A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of antidiabetic medicinal product may be considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia was the most frequently reported observed adverse reaction during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua (see section 4.8). Hypoglycaemia may occur if the dose of Suliqua is higher than required.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">necessitate dose adjustment. These factors include: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">change in the injection area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improved insulin sensitivity (e.g. by removal of stress factors) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">unaccustomed, increased or prolonged physical activity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intercurrent illness (e.g. vomiting, diarrhoea) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inadequate food intake </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">missed meals </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alcohol consumption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adrenocortical insufficiency) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant treatment with certain other medicinal products (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide and/or insulin in combination with a sulfonylurea may result in an increased risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypoglycaemia. Therefore Suliqua should not be given in combination with a sulfonylurea.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The dose of Suliqua must be individualised based on clinical response and is titrated based on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patient&#x2019;s need for insulin (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Acute pancreatitis  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. There </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been few reported events of acute pancreatitis with lixisenatide although a causal relationship has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not been established. Patients should be informed of the characteristic symptoms of acute pancreatitis: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">persistent, severe abdominal pain. If pancreatitis is suspected, Suliqua should be discontinued; if acute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pancreatitis is confirmed, lixisenatide should not be restarted. Caution should be exercised in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a history of pancreatitis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:770pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Severe gastrointestinal disease  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.8). Suliqua has not been studied in patients with severe gastrointestinal disease, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">severe gastroparesis and therefore, the use of Suliqua is not recommended in these patients.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Severe renal impairment  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no therapeutic experience in patients with severe renal impairment (creatinine clearance less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than 30 ml/min) or end-stage renal disease. Use is not recommended in patients with severe renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment or end-stage renal disease (see sections 4.2 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concomitant medicinal products  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered medicinal products. Suliqua should be used with caution in patients receiving oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have a narrow therapeutic ratio. Specific recommendations regarding intake of such medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products are given in section 4.5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dehydration  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients treated with Suliqua should be advised of the potential risk of dehydration in relation to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gastrointestinal adverse reactions and take precautions to avoid fluid depletion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antibody formation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of Suliqua may cause formation of antibodies against insulin glargine and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide. In rare cases, the presence of such antibodies may necessitate adjustment of the Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose in order to correct a tendency for hyperglycaemia or hypoglycaemia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Avoidance of medication errors  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients must be instructed to always check the pen label before each injection to avoid accidental </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mix-ups between the two different strengths of Suliqua and mix-ups with other injectable diabetes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">To avoid dosing errors and potential overdose, neither the patients nor healthcare professionals should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ever use a syringe to draw the medicinal product from the cartridge in the pre-filled pen into a syringe. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antidiabetic medicinal products not studied in combination with Suliqua   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua has not been studied in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sulfonylureas, glinides, and pioglitazone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Travel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">To avoid dosing errors and potential overdoses with changing to different time zones, the patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should seek the doctor&#x2019;s advice before travelling. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&apos;sodium-free&apos;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product contains metacresol, which may cause allergic reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interaction studies with Suliqua have been performed. The information given below is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies with the monocomponents.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic interactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A number of substances affect glucose metabolism and may require dose adjustment of Suliqua. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pentoxifylline, propoxyphene, salicylates and sulphonamide antibiotics. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">olanzapine) and protease inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sometimes be followed by hyperglycaemia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetic interactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide is a peptide and is not metabolised by cytochrome P450. In </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies, lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">did not affect the activity of cytochrome P450 isozymes or human transporters tested. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No pharmacokinetic interactions are known for insulin glargine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effect of gastric emptying on oral medicinal products </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered medicinal products. Patients receiving medicinal products of either a narrow therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ratio or medicinal products that require careful clinical monitoring should be followed closely, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">especially at the time of initiation of lixisenatide treatment. These medicinal products should be taken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in a standardised way in relation to lixisenatide. If such medicinal products are to be administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">food, patients should be advised to, if possible, take them with a meal when lixisenatide is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or 4 hours after lixisenatide injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastro-resistant formulations containing substances sensitive to stomach degradation, should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered 1 hour before or 4 hours after lixisenatide injection.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:12pt">Paracetamol</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paracetamol was used as a model medicinal product to evaluate the effect of lixisenatide on gastric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emptying. Following administration of a single dose of paracetamol 1000 mg, paracetamol AUC and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1/2 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were unchanged whatever the timing of its administration (before or after the lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injection). When administered 1 or 4 hours after 10 mcg lixisenatide, C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of paracetamol was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased by 29% and 31%, respectively and median t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was delayed by 2.0 and 1.75 hours, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively. A further delay in t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and a reduced C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of paracetamol have been predicted with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 mcg maintenance dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No effects on paracetamol C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> were observed when paracetamol was administered 1 hour </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">before lixisenatide. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on these results, no dose adjustment for paracetamol is required but the delayed t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when paracetamol is administered 1-4 hours after lixisenatide should be taken into account when a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rapid onset of action is required for efficacy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Oral contraceptives </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.03 mg/levonorgestrel 0.15 mg) 1 hour before or 11 hours after 10 mcg lixisenatide, the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1/2</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of ethinylestradiol and levonorgestrel were unchanged. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of the oral contraceptive 1 hour or 4 hours after lixisenatide did not affect AUC and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1/2 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of ethinylestradiol and levonorgestrel, whereas C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of ethinylestradiol was decreased by 52% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39%, respectively and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of levonorgestrel was decreased by 46% and 20%, respectively and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">median t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was delayed by 1 to 3 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The reduction in C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is of limited clinical relevance and no dose adjustment for oral contraceptives is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">required. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Atorvastatin </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When lixisenatide 20 mcg and atorvastatin 40 mg were co-administered in the morning for 6 days, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure to atorvastatin was not affected, while C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was decreased by 31% and t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was delayed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.25 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No such increase for t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was observed when atorvastatin was administered in the evening and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide in the morning but the AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of atorvastatin were increased by 27% and 66%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These changes are not clinically relevant and, therefore, no dose adjustment for atorvastatin is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when co-administered with lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Warfarin and other coumarin derivatives </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After concomitant administration of warfarin 25 mg with repeated dosing of lixisenatide 20 mcg, there </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were no effects on AUC or INR (International Normalised Ratio) while C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was reduced by 19% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was delayed by 7 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on these results, no dose adjustment for warfarin is required when co-administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide; however, frequent monitoring of INR in patients on warfarin and/or coumarin derivatives </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is recommended at the time of initiation or ending of lixisenatide treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Digoxin </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After concomitant administration of lixisenatide 20 mcg and digoxin 0.25 mg at steady state, the AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of digoxin was not affected. The t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of digoxin was delayed by 1.5 hour and the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was reduced by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">26%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on these results, no dose adjustment for digoxin is required when co-administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ramipril </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After concomitant administration of lixisenatide 20 mcg and ramipril 5 mg during 6 days, the AUC of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ramipril was increased by 21% while the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was decreased by 63%. The AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolite (ramiprilat) were not affected. The t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of ramipril and ramiprilat were delayed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 2.5 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on these results, no dose adjustment for ramipril is required when co-administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is not recommended in women of childbearing potential not using contraception. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinical data on exposed pregnancies from controlled clinical studies with use of Suliqua, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine, or lixisenatide.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) with insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine indicate no malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indicate reproductive toxicity with insulin glargine.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no or limited amount of data from the use of lixisenatide in pregnant women. Studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide in animals have shown reproductive toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua is not recommended during pregnancy and in women of childbearing potential not using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraception. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether insulin glargine or lixisenatide are excreted in human milk. A risk to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with lixisenatide or insulin glargine do not indicate direct harmful effects with respect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to fertility.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua has no or negligible influence on the ability to drive or use machines.</span><span style="font-family:ArialMT,sans-serif;font-size:9.96pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However, the patient&apos;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for example, as a result of visual impairment. This may constitute a risk in situations where these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abilities are of special importance (e.g. driving a car or using machines). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be advised to take precautions to avoid hypoglycaemia while driving and using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machines. This is particularly important in those who have reduced or absent awareness of the warning </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">whether it is advisable to drive or use machines in these circumstances. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most frequently reported adverse reactions during treatment with Suliqua were hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and gastrointestinal adverse reactions (see section &apos;Description of selected adverse reactions&apos; below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following related adverse reactions from clinical investigations are listed below by system organ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">class and in order of decreasing frequency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(very common: &#x2265;1/10; common: &#x2265;1/100 to</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> &lt;1/10; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">uncommon: &#x2265;1/1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">000 to &lt;1/100; rare: &#x2265;1/10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 000 to &lt;1/1 000; very rare: &lt;1/10 000; not known: cannot </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be estimated from the available data). Within each frequency grouping, adverse reactions are presented </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:72pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:72pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1: Adverse drug reactions reported  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:72pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">System organ </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:72pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">class </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:204pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:158pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Very common Common </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:300pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Uncommon </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:390pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Rare </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:476pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Not Known </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infestations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nasopharyngitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tract infection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Urticaria  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Headache  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diarrhoea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vomiting  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dyspepsia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Delayed gastric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emptying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">amyloidosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lipodystrophy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:72pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:158pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:230pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:476pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypoglycaemia  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table describes the rate of documented symptomatic hypoglycaemia </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 3.9 mmol/L) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">severe hypoglycaemia for both Suliqua and the comparator***. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:298pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:72pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 2: Documented symptomatic or severe hypoglycaemic adverse reactions </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:205pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin na&#xef;ve patients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:349pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Switch from </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:349pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">basal insulin </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:435pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Switch from GLP-1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:435pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">receptor agonist*** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:124pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:182pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:228pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:275pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide Suliqua Insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:426pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:490pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">GLP-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:481pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agonist*** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:123pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:192pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">469 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:238pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">467 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:295pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">233 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">365 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">365 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:437pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">255 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:497pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">256 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Documented </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">symptomatic </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">hypoglycaemia* </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:127pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:246pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:445pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:505pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:505pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:87pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with event, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:87pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> n (%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">120  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:180pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(25.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:235pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">110  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(23.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:246pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:295pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:286pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(6.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:303pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:346pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">146  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:336pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(40.0%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">155  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(42.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:437pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:425pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(27.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:500pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:488pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:503pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:503pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Events per patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:195pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.44 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:241pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:298pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.34 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.03 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:394pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:493pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.08 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Severe </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:78pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">hypoglycaemia** </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:198pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:244pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:301pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:354pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:503pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Events per patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">year,  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:760pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:202pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:238pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;0.01 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:351pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.02 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:391pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;0.01 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:437pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;0.01 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:507pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* Documented symptomatic hypoglycaemia was an event during which typical symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypoglycaemia </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were accompanied by a measured plasma glucose concentration of &#x2264;3.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9 mmol/L. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">** Severe symptomatic hypoglycaemia was an event requiring assistance of another person to actively </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administer carbohydrate, glucagon, or other resuscitative actions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*** Liraglutide, exenatide BID (twice in a day) or extended release, dulaglutide or albiglutide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastrointestinal disorders  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal adverse reactions (nausea, vomiting and diarrhoea) were frequently reported adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions during the treatment period. In patients treated with Suliqua, the incidence of related nausea, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea and vomiting was 8.4%, 2.2% and 2.2%, respectively. Gastrointestinal adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were mostly mild and transient in nature.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Allergic reactions (urticaria) possibly related with Suliqua have been reported in 0.3% of patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of generalised allergic reaction including anaphylactic reaction and angioedema have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported during marketed use of insulin glargine and lixisenatide.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immunogenicity  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of Suliqua may cause formation of antibodies against insulin glargine and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of formation of anti-insulin glargine antibodies was 21% and 26.2%. In approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">93% of the patients, anti-insulin glargine antibodies showed cross-reactivity to human insulin. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">incidence of formation of anti-lixisenatide antibodies was approximately 43%. Neither status for anti-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine antibodies nor for anti-lixisenatide antibodies had a clinically relevant impact on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety or efficacy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lipodystrophy and cutaneous amyloidosis may occur at the injection site of insulins and delay local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin absorption. Continuous rotation of the injection site within the given injection area may help to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduce or prevent these reactions (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Injection site reactions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some (1.7%) patients using insulin containing therapy, including Suliqua have experienced erythema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">local oedema, and pruritus at the site of injection.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Heart rate </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Increase in heart rate has been reported with GLP-1 receptor agonist use and a transient increase was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also observed in some studies with lixisenatide. No increase in mean heart rate was seen in all phase 3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies with Suliqua. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia and gastrointestinal adverse reactions may develop if a patient is dosed with more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua than required. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the medicinal product, meal patterns, or physical activity may be needed. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">More severe episodes of hypoglycaemia with coma, seizure, or neurologic impairment may be treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carbohydrate intake and observation may be necessary because hypoglycaemia may recur after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apparent clinical recovery. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In case of gastrointestinal adverse reactions, appropriate supportive treatment should be initiated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">according to the patient&#x2019;s clinical signs and symptoms. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC Code: A10AE54. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua combines two active substances with complementary mechanisms of action to improve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glycaemic control: insulin glargine, a basal insulin analogue (mainly targeting fasting plasma glucose), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and lixisenatide, a GLP-1 receptor agonist (mainly targeting postprandial glucose). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and enhances protein synthesis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lixisenatide  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide is a GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endogenous incretin hormone that potentiates glucose-dependent insulin secretion from beta cells and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suppresses glucagon from alpha cells in the pancreas.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypoglycaemia, the rescue mechanism of glucagon secretion is preserved. A postprandial injection of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">absorbed and appears in the circulation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic effects  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The combination of insulin glargine and lixisenatide has no impact on the pharmacodynamics of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine. The impact of the combination of insulin glargine and lixisenatide on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacodynamics of lixisenatide has not been studied in phase 1 studies.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Consistent with a relatively constant concentration/time profile of insulin glargine over 24 hours with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">no pronounced peak when administered alone, the glucose utilisation rate/time profile was similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when given in the insulin glargine/lixisenatide combination.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The time course of action of insulins, including Suliqua, may vary between individuals and within the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">same individual.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In clinical studies with insulin glargine (100 units/ml) the glucose-lowering effect on a molar basis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(i.e., when given at the same doses) of intravenous insulin glargine is approximately the same as that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for human insulin.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lixisenatide </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a 28-day placebo-controlled study in patients with type 2 diabetes 5 to 20 mcg lixisenatide resulted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in a statistically significant decreases in postprandial blood glucose after breakfast, lunch and dinner. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastric emptying  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following a standardised labelled test meal, in the study referred to above, it was confirmed that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide slows gastric emptying, thereby reducing the rate of postprandial glucose absorption. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">slowing effect of gastric emptying was maintained at the end of the study.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy and safety  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and effectiveness of Suliqua on glycaemic control were evaluated in three randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical studies in patients with type 2 diabetes mellitus:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Add-on to metformin [insulin na&#xef;ve] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Switch from basal insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:97pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Switch from GLP-1 receptor agonist  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In each of the active-controlled clinical studies, treatment with Suliqua produced clinically and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">statistically significant improvements in haemoglobin A1c (HbA1c). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reaching lower HbA1c levels and achieving greater HbA1c reduction did not increase rates of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypoglycaemia with combination treatment versus insulin glargine alone (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the Add-on to metformin clinical study the treatment was started at 10 dose steps (10 units insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine and 5 mcg lixisenatide). In the switch from basal insulin clinical study the starting dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20 dose steps (20 units insulin glargine and 10 mcg lixisenatide) or 30 dose steps, (30 units insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine and 10 mcg lixisenatide), see section 4.2, depending on the previous insulin dose. In both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies the dose was titrated once weekly, based on fasting self-measured plasma glucose values. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Add-on to metformin [insulin na&#xef;ve]  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Clinical study in patients with Type 2 diabetes insufficiently controlled on an oral anti-diabetic (OAD) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A total of 1170 patients with type 2 diabetes were randomised in an open label, 30-week, active-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">controlled study to evaluate the efficacy and safety of Suliqua compared to the individual components, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine (100 units/ml) and lixisenatide (20 mcg).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with type 2 diabetes, treated with metformin alone or metformin and a second OAD treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that could be a sulfonylurea or a glinide or a SGLT-2 inhibitor or a dipeptidyl peptidase-4 (DPP-4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor, and who were not adequately controlled with this treatment (HbA1c range 7.5% to 10% for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients previously treated with metformin alone and 7% to 9% for patients previously treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metformin and a second oral anti-diabetic treatment) entered a run-in period for 4 weeks. During this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">run-in phase metformin treatment was optimised and any other OADs were discontinued. At the end </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the run-in period, patients who remained inadequately controlled (HbA1c between 7% and 10%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were randomised to either Suliqua, insulin glargine or lixisenatide. Of the 1479 patients who started </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the run-in phase, 1170 were randomised. The main reasons for not entering the randomised phase were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">FPG value &gt;13.9 mmol/L and HbA1c value &lt;7% or &gt;10% at the end of the run-in phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The randomised type 2 diabetes population had the following characteristics: Mean age was 58.4 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with the majority (57.1%) being aged of 50 to 64 years, and 50.6 percent were male. The mean BMI at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline was 31.7 kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with 63.4% of patients having a BMI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;30</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. The mean duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes was approximately 9 years. Metformin was a mandatory background therapy and 58% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients received a second OAD at screening, being a sulfonylurea in 54% of patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 30, Suliqua provided statistically significant improvement in HbA1c (p-value &lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the individual components. In a pre-specified analysis of this primary endpoint, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">differences observed were consistent with regard to baseline HbA1c (&lt;8% or </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8%) or baseline OAD </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use (metformin alone or metformin plus second OAD). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">See table and figure below for the other endpoints in the study.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3: Results at 30 weeks - Add-on to metformin clinical study (mITT population) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:282pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:349pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:450pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lixisenatide </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number of subjects (mITT)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">468 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">466 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">233 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HbA1c (%)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:266pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean; post run-in phase)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:293pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:472pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:293pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:472pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:291pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference vs. insulin glargine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:362pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-0.4, -0.2] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference vs. lixisenatide  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:266pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-0.9, -0.7] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Number of patients (%) reaching </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HbA1c &lt;7% at week 30*  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">345 (74%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">277 (59%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">77 (33%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fasting plasma glucose (mmol/L)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:300pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:479pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.88 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.79 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.53  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.27  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus glargine (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-0.420 to 0.038] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:368pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.1017) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.96 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-2.246 to -1.682] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2 hour PPG (mmol/L)** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15.19  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:374pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14.61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:466pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14.72  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.15  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:374pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">11.35  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.99  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:288pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-5.68  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.31 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-4.58 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus glargine (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:375pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-2.38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-2.79 to -1.96) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.10   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:445pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-1.63 to -0.57) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Mean body weight (kg)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">89.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">89.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">90.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:291pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:470pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-2.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Comparison versus insulin glargine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:358pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-1.9 to -0.9] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Comparison versus lixisenatide  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]*  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.01 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:454pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[1.4 to 2.6] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number (%) of patients achieving </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HbA1c &lt;7% with no body weight </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">gain at week 30  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">202  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:282pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(43.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">117  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:368pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(25.1%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">65  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(27.9%) </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Proportion difference vs. insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">18.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:356pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[12.2 to 24.0] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:364pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:479pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Proportion difference vs. lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]*  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:469pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[8.1 to 22.4]</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine daily dose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS insulin dose at week 30 (mean)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:290pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">39.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">40.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">*Not included in the pre-specified step-down testing procedure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">**2 hour PPG minus the pre-meal glucose value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Figure 1: Mean HbA1c (%) by visit during 30-week randomised treatment period - mITT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">population </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in the Suliqua group reported a statistically significantly greater decrease in the average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7-point self-monitored plasma glucose (SMPG) profile from baseline to Week 30 (-3.35 mmol/L) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to patients in the insulin glargine group (-2.66 mmol/L; difference -0.69 mmol/L) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the lixisenatide group (-1.95 mmol/L; difference -1.40 mmol/L) (p&lt;0.0001 for both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparisons). At all time points, 30-week mean plasma glucose values were lower in the Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in both the insulin glargine group and the lixisenatide group, with the only exception of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pre-breakfast value which was similar between the Suliqua group and the insulin glargine group.</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Switch from basal insulin  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:12pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Clinical study in patients with Type 2 diabetes insufficiently controlled on basal insulin </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A total of 736 patients with type 2 diabetes participated in a randomised, 30-week, active-controlled, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">open-label, 2-treatment arm, parallel-group, multicentre study to evaluate the efficacy and safety of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua compared to insulin glargine (100 units/ml).</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients screened had type 2 diabetes were treated with basal insulin for at least 6 months, receiving a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stable daily dose of between 15 and 40 U alone or combined with 1 or 2 OADs (metformin or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sulfonylurea or a glinide or a SGLT-2 inhibitor or a DPP-4 inhibitor), had an HbA1c between 7.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 10% (mean HbA1c of 8.5% at screening) and a FPG less than or equal to 10.0 mmol/L or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">11.1 mmol/L depending on their previous anti-diabetic treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After screening, eligible patients (n=1018) entered a 6 week run-in phase where patients remained on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or switched to insulin glargine, in case they took another basal insulin, and had their insulin dose </span></p>
<img style="position:absolute;top:275pt;left:101pt;width:252pt;height:195pt" src="data:image/png;base64,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">
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated/stabilised while continuing metformin (if previously taken). Any other OADs were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">discontinued.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At the end of the run-in period, patients with an HbA1c between 7 and 10%, FPG </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.77 mmol/L and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine daily dose of 20 to 50 units, were randomised to either Suliqua (n=367) or insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine (n=369). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This type 2 diabetes population had the following characteristics: mean age was 60.0 years with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">majority (56.3%) being aged of 50 to 64 years, and 53.3 percent were female. The mean BMI at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline was 31.1 kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> with 57.3% of patients having a BMI </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;30 kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. The mean diabetes duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was approximately 12 years and the mean duration of previous basal insulin treatment was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 3 years. At screening 64.4% of patients were receiving insulin glargine as basal insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 95% received at least 1 concomitant OAD.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 30, Suliqua provided statistically significant improvement in HbA1c (p-value &lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to insulin glargine.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">See table and figure below for the other endpoints in the study. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4: Results at 30 weeks - Study Type 2 diabetes uncontrolled on basal insulin mITT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">population </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:77pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:330pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:423pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number of subjects (mITT) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">366 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:452pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">365 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HbA1c (%) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:403pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean; post run-in phase)   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:454pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of treatment (mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:454pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean)   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:452pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference versus insulin glargine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:403pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-0.6, -0.4] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients [n (%)] reaching HbA1c &lt;7% at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 30*  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">201 (54.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:433pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">108 (29.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fasting plasma glucose (mmol/L)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:349pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:461pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.78 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.69 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.35 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference versus insulin glargine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:380pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-0.21 to 0.43) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2 hour PPG (mmol/L)** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:336pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14.85 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14.97  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.91  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.41  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-4.72  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.39 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus glargine (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-3.89 to -2.77) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Mean body weight (kg)</span></b><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">87.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:454pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Comparison versus  insulin glargine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:403pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:384pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[-1.8 to -0.9] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number (%) of patients achieving HbA1c&lt; </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7% with no body weight gain at week 30 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">125  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:331pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(34.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">49  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:443pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(13.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Proportion difference versus insulin glargine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95%  confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">20.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:382pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[15.0 to 26.7] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:77pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine daily dose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:349pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)</span><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt"> </span></b></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">35.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Endpoint (mean)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS insulin dose change at week 30 (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">*Not included in the pre-specified step-down testing procedure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">**2 hour PPG minus the pre-meal glucose value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Figure 2:  Mean HbA1c (%) by visit during 30-week randomised treatment period - mITT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">population  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Switch from GLP-1 receptor agonist </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Clinical study in patients with Type 2 diabetes insufficiently controlled on GLP-1 receptor agonist </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy and safety of Suliqua compared to unchanged pre-trial GLP-1 receptor agonist treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were studied in a 26-week, randomised, open-label trial. The trial included 514 patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus inadequately controlled (HbA1c level of 7% to 9% both inclusive) while treated for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at least 4 months with liraglutide or exenatide or for at least 6 months with dulaglutide, albiglutide or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exenatide extended release, all at maximal tolerated dose, and metformin alone or in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pioglitazone, a SGLT-2 inhibitor or both. Eligible patients were randomised to either receive Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or to continue their previous GLP-1 receptor agonist both on top of their previous oral anti-diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At screening, 59.7% of the subjects received a once or twice-daily GLP-1 receptor agonist and 40.3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">received a once weekly GLP-1 receptor agonist. At screening, 6.6% of the subjects received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pioglitazone, and 10.1% a SGLT-2 inhibitor in combination with metformin. The study population had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the following characteristics: mean age was 59.6 years, 52.5% of the subjects were male. The mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">duration of diabetes was 11 years, the mean duration of previous GLP-1 receptor agonist treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was 1.9 years, the mean BMI was approximately 32.9 kg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, mean eGFR was 87.3 ml/min/1.73 m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 90.7% of patients had an eGFR &#x2265;60 m</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">l/min.  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At week 26, Suliqua provided statistically significant improvement in HbA1c (p &lt;0.0001). A pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">specified analysis by GLP-1 receptor agonist subtype (once/twice daily or weekly formulation) used at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">screening showed that HbA1c change at week 26 was similar for each subgroup and consistent with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the primary analysis for the overall population. The mean daily dose of Suliqua at Week 26 was 43.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose steps. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">See table and figure below for the other endpoints in the study.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5: Results at 26 weeks - Study Type 2 diabetes uncontrolled on GLP-1 receptor agonist </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">mITT population  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt;color:#0000ff"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:330pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Suliqua </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:423pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">GLP-1 receptor </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:441pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">agonist*  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number of subjects (mITT)   </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">252 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:452pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">253 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HbA1c (%)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:305pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean; post run-in phase)    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:453pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of treatment (mean)                    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:341pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:453pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean)       </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:452pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference versus GLP-1 receptor agonist   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.6 [-0.8, -0.5] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Patients [n (%)] reaching HbA1c &lt;7% at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">week 26  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:321pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">156 (61.9%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:436pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">65 (25.7%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Proportion difference (95% confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interval) vs GLP-1 receptor agonist  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:361pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">36.1% (28.1% to 44%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:396pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;.0001</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fasting plasma glucose (mmol/L)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:348pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:460pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)      </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.06 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.45 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean)     </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6.86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8.66 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean)    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-2.28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Difference versus GLP-1 receptor agonist   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.67 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-2.00 to -1.34) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2 hour PPG (mmol/L)**    </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)           </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:336pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.78 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">End of study (mean)    </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9.68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12.59 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">    </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-4.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS difference versus GLP-1 receptor agonist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(mean)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]                                  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:89pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:403pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-2.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-3.42 to -2.28) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Mean body weight (kg)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:460pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#ff0000"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Baseline (mean)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:336pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">93.01 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">95.49 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">LS change from baseline (mean) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.89 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Comparison versus  GLP-1 receptor agonist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">[95% confidence interval]  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p-value) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.03 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:376pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(2.417 to 3.643) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;0.0001)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#ff0000"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">* Liraglutide, exenatide BID or extended release, dulaglutide or albiglutide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">**2 hour PPG minus the pre-meal glucose value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:88pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Figure 3: Mean HbA1c (%) by visit during 26-week randomised treatment period- mITT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">population  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Concomitant use of Suliqua with SGLT-2 inhibitors (SGLT2i)  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The concomitant use of Suliqua with SGLT2i is supported by subgroup analyses from three phase 3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised clinical studies (119 patients on the insulin glargine/lixisenatide fixed ratio combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(FRC) who also received SGLT2i).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One study conducted in Europe and North America included data from 26 patients (10.1%) who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitantly received insulin glargine/lixisenatide FRC, metformin and an SGLT2i. Two more phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 studies from the dedicated Japanese clinical development program performed in patients not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reaching sufficient glycaemic control on OADs provided data for 59 patients (22.7%) and 34 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(21.1%), respectively, who concomitantly received SGLT2i and insulin glargine/lixisenatide FRC. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The data from these 3 studies show that initiation of Suliqua in patients inadequately controlled with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment including SGLT2i leads to improved change in HbA1c versus the comparators (insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine, lixisenatide, liraglutide, exenatide BID or extended release, dulaglutide or albiglutide). There </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was no increased risk of hypoglycaemia and no relevant differences in the overall safety profile in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">SGLT2i users compared to non-users. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cardiovascular outcome studies  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The cardiovascular safety of insulin glargine and lixisenatide has been established in the ORIGIN and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ELIXA clinical studies, respectively. No dedicated cardiovascular outcome trial has been conducted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with Suliqua. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised, 12,537 patient study that compared insulin glargine 100 Units to standard care on the time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to first occurrence of a major adverse cardiovascular event (MACE). MACE was defined as the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite of cardiovascular (CV) death, nonfatal myocardial infarction and nonfatal stroke. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">median duration of study follow-up was 6.2 years. The incidence of MACE was similar between </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine 100 Units and standard care in ORIGIN [Hazard Ratio (95% CI) for MACE; 1.02 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.94, 1.11)].  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lixisenatide </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The ELIXA study was a randomised, double-blind, placebo-controlled, multinational study that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluated CV outcomes during treatment with lixisenatide in patients (n=6068) with type 2 diabetes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mellitus after a recent Acute Coronary Syndrome. The primary composite efficacy endpoint was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">time to the first occurrence of any of the following events: CV death, non-fatal myocardial infarction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-fatal stroke, or hospitalisation for unstable angina.  The median duration of study follow-up was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">25.8 and 25.7 months in the lixisenatide group and the placebo group, respectively.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of the primary endpoint was similar in the lixisenatide (13.4%) and placebo (13.2%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">groups: the hazard ratio (HR) for lixisenatide versus placebo was 1.017, with an associated 2-sided </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">95% confidence interval (CI) of 0.886 to 1.168.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has waived the obligation to submit the results of studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua in all subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2 for information on paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><i><span style="font-family:Arial,sans-serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The insulin glargine/lixisenatide ratio has no relevant impact on the PK of insulin glargine and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lixisenatide in Suliqua.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After subcutaneous administration of insulin glargine/lixisenatide combinations to patients with type 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes, insulin glargine showed no pronounced peak. Exposure to insulin glargine following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of the insulin glargine/lixisenatide combination was 86-88 % compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of separate simultaneous injections of insulin glargine and lixisenatide. This difference </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not considered clinically relevant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After subcutaneous administration of insulin glargine/lixisenatide combinations to patients with type 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes, the median t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of lixisenatide was in the range of 2.5 to 3.0 hours. AUC was comparable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">while there was a small decrease in C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of lixisenatide of 22-34% compared with separate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneous administration of insulin glargine and lixisenatide, which is not likely to be clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no clinically relevant differences in the rate of absorption when lixisenatide as monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is administered subcutaneously in the abdomen, deltoid, or thigh.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The apparent volume of distribution of insulin glargine after subcutaneous administration of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insulin glargine/lixisenatide combinations (Vss/F) is approximately 1700 L. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide has a low level (55%) of binding to human proteins. The apparent volume of distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of lixisenatide after subcutaneous administration of insulin glargine/lixisenatide combinations (Vz/F) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is approximately 100 L.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A metabolism study in diabetic patients who received insulin glargine alone indicates that insulin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glargine is rapidly metabolised at the carboxyl terminus of the B chain to form two active metabolites, </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compound is the metabolite M1. The pharmacokinetic and pharmacodynamic findings indicate that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As a peptide, lixisenatide is eliminated through glomerular filtration, followed by tubular reabsorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and subsequent metabolic degradation, resulting in smaller peptides and amino acids, which are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reintroduced in the protein metabolism. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After single subcutaneous administration of the insulin glargine/lixisenatide combination, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">apparent clearance (CL/F) of insulin glargine was approximately 120 L/h. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After multiple-dose subcutaneous administration of Lixisenatide in patients with type 2 diabetes, mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">terminal half-life was approximately 3 hours and the mean apparent clearance (CL/F) about 35 L/h. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In subjects with mild (creatinine clearance calculated by the Cockcroft-Gault formula 60-90 ml/min), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">moderate (creatinine clearance 30-60 ml/min) and severe renal impairment (creatinine clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15-30 ml/min) AUC of lixisenatide was increased by 46%, 51% and 87%, respectively.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Insulin glargine has not been studied in patients with renal impairment. In patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, however, insulin requirements may be diminished due to reduced insulin metabolism.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As lixisenatide is cleared primarily by the kidney, no pharmacokinetic study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with acute or chronic hepatic impairment. Hepatic dysfunction is not expected to affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetics of lixisenatide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Insulin glargine has not been studied in diabetes patients with hepatic impairment. In patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatic impairment, insulin requirements may be diminished due to reduced capacity for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gluconeogenesis and reduced insulin metabolism. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Age, race, gender and body weight  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Insulin glargine </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect of age, race, and gender on the pharmacokinetics of insulin glargine has not been evaluated. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">controlled clinical studies in adults with insulin glargine (100 units/ml), subgroup analyses based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, race, and gender did not show differences in safety and efficacy.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lixisenatide </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Age has no clinically relevant effect on the pharmacokinetics of lixisenatide. In a pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study in elderly non-diabetic subjects, administration of lixisenatide 20 mcg resulted in a mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase of lixisenatide AUC by 29% in the elderly population (11 subjects aged 65 to 74 years and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects aged &#x2265;75 years) compared to 18</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> subjects aged 18 to 45 years, likely related to reduced renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function in the older age group.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ethnic origin had no clinically relevant effect on the pharmacokinetics of lixisenatide based on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results of pharmacokinetic studies in Caucasian, Japanese and Chinese subjects. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gender has no clinically relevant effect on the pharmacokinetics of lixisenatide  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Body weight has no clinically relevant effect on lixisenatide AUC.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immunogenicity  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the presence of anti-lixisenatide antibodies, lixisenatide exposure and variability in exposure are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">markedly increased regardless of the dose level. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No studies have been performed with Suliqua in children and adolescents below 18 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No animal studies have been conducted with the combination of insulin glargine and lixisenatide to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evaluate repeated dose toxicity, carcinogenesis, genotoxicity, or toxicity to reproduction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Insulin glargine  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical data for insulin glargine reveal no special hazard for humans based on conventional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reproduction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lixisenatide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 2-year subcutaneous carcinogenicity studies, non-lethal C-cell thyroid tumours were seen in rats </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and mice and are considered to be caused by a non-genotoxic GLP-1 receptor-mediated mechanism to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">which rodents are particularly sensitive. C-cell hyperplasia and adenoma were seen at all doses in rats </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and a no observed adverse effect level (NOAEL) could be not defined. In mice, these effects occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at exposure ratio above 9.3-fold when compared to human exposure at the therapeutic dose. No C-cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carcinoma was observed in mice and C-cell carcinoma occurred in rats with an exposure ratio relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to exposure at human therapeutic dose of about 900-fold.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 2-year subcutaneous carcinogenicity study in mice, 3 cases of adenocarcinoma in the endometrium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were seen in the mid dose group with a statistically significant increase, corresponding to an exposure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ratio of 97-fold. No treatment-related effect was demonstrated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies did not indicate direct harmful effects with respect to male and female fertility in rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reversible testicular and epididymal lesions were seen in dogs treated with lixisenatide. No related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect on spermatogenesis was seen in healthy men. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In embryo-foetal development studies, malformations, growth retardation, ossification retardation and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">skeletal effects were observed in rats at all doses (5-fold exposure ratio compared to human exposure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and in rabbits at high doses (32-fold exposure ratio compared to human exposure) of lixisenatide. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">both species, there was a slight maternal toxicity consisting of low food consumption and reduced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">body weight. Neonatal growth was reduced in male rats exposed to high doses of lixisenatide during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">late gestation and lactation, with a slightly increased pup mortality observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Glycerol 85% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Methionine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metacresol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Zinc chloride </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concentrated hydrochloric acid (for pH adjustment) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium hydroxide (for pH adjustment) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Water for injections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product must not be mixed with other medicinal products.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf-life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before first use  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After first use</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">28 days.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After first use: Store below 25&#xb0;C. Do not refrigerate. Do not freeze. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store with attached needle. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store pen away from direct heat or direct light. The pen cap must be put back on the pen after each </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">injection in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in a refrigerator (2&#xb0;C - 8&#xb0;C).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not freeze or place next to the freezer compartment or a freezer pack.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Keep the pre-filled pen in the outer carton in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For storage conditions after first opening of the medicinal product, see section 6.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Type I colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(aluminium) with inserted laminated sealing disks (bromobutyl rubber on the medicinal product side </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and polyisoprene on the outside) containing 3 ml of solution. Each cartridge is assembled into a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disposable pen.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Packs of 3, 5 and 10 pre-filled pens. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal and other handling </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before first use, the pen must be taken out of the refrigerator and stored below 25&#xb0;C for 1 to 2 hours.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The cartridge should be inspected before use. It must only be used if the solution is clear, colourless, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with no solid particles visible, and if it is of water-like consistency.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Suliqua must not be mixed with any other insulin or diluted. Mixing or diluting can change its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">time/action profile and mixing can cause precipitation.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A new needle must always be attached before each use. Needles must not be re-used. The patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should discard the needle after each injection. Needles are not included in the pack. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the event of blocked needles patients must follow the instructions described in the &#x201c;Instructions for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Use&#x201d; accompanying the package leaflet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Empty pens must never be reused and must be properly discarded.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">To prevent the possible transmission of disease, each pen must be used by one patient only.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The label must always be checked before each injection to avoid medication errors between Suliqua </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and other injectable anti-diabetic medicinal products, including the 2 different pens of Suliqua (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Before using Suliqua, the instructions for use included in the package leaflet must be read carefully.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/16/1157/006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 11 January 2017 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 22 November 2021 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:214pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>

























































</body>
</html> 

